Background. Autosomal-dominant medullary cystic kidney disease type 2 (MCKD2) is a tubulointerstitial nephropathy that causes renal salt wasting, hyperuricemia, gout, and end-stage renal failure in the fifth decade of life. The chromosomal locus for MCKD2 was localized on chromosome 16p12. Within this chromosomal region, Uromodulin (UMOD) was located as a candidate gene. UMOD encodes the Tamm-Horsfall protein. By sequence analysis, one group formerly excluded UMOD as the disease-causing gene. In contrast, recently, another group described mutations in the UMOD gene as responsible for MCKD2 and familial juvenile hyperuricemic nephropathy (FJHN).
Medullary cystic kidney disease type 2 (MCKD2) (OMIM 603860) includes clinical features of reduced urinary concentration, salt wasting, and end-stage renal failure. In contrast to MCKD1, in MCKD2, a more severe phenotype concerning hyperuricemia and gout has been described. Moreover, in MCKD2, an earlier median age of onset has been reported (age of onset in MCKD2 is 32 years of age compared to 62 years in MCKD1) [1] . Otherwise, these two diseases are clinically undistinguishable. In MCKD, small corticomedullary cysts are common, but not always detected. Kidney size is normal or slightly reduced. MCKD shows a renal histologic triad of (1) tubular basement disintegration, (2) tubular atrophy with cyst development at the corticomedullary border, and (3) interstitial cell infiltration associated with fibrosis [2] . Neither imaging results, nor pathologic findings, are pathognomic for MCKD2. The condition shares clinical and morphologic similarities to recessive juvenile nephronophthisis (NPH) [3] . In contrast to juvenile onset in NPH, end-stage renal failure in MCKD occurs in adulthood. Moreover NPH is inherited in an autosomal-recessive pattern, whereas MCKD is autosomal-dominant.
Two loci for MCKD have been described: MCKD1 showed linkage to chromosome 1q21 in two Cypriot families [4] and MCKD2 was localized on chromosome 16p12 in an Italian family [1] . Two groups showed independently that loci for familial juvenile hyperuremic nephropathy (FJHN) and MCKD2 mapped to the same chromosomal region on 16p12 [5, 6] , assuming that FJHN and MCKD2 might be different facets of the same disease caused by mutations in one and the same gene. Later, an additional FJHN locus was mapped to a more centromeric region [7] on chromosome 16, resulting in two different FJHN loci, which are overlapped by the MCKD2 locus [8] . Two years after publication of the chromosomal candidate region of MCKD2, Uromodulin (UMOD) was published as excluded from representing the disease-causing gene [9] . In contrast however, Hart et al [10] later detected four different mutations in the UMOD gene, indicating that this is the gene responsible for FJHN and MCKD2.
UMOD encodes the Tamm-Horsfall protein (THP), which is expressed primarily at the luminal side of renal epithelial cells of the thick ascending loop of Henle and of early distal convoluted tubules. THP is the most abundant protein in the urine of humans [11] . Functional roles of UMOD have been described in urinary tract infections, in binding to complement factors, in myeloma kidney, and nephrolithiasis [12] [13] [14] [15] . The UMOD protein contains (1) a zona pellucida domain (ZP), which is necessary for polymerization into the supramolecular structure of a filament, (2) an elastase-sensitive fragment containing three calcium-binding epidermal growth factor (EGF)-like domains and a signal peptide, and (3) a potential glycosyl-phosphatidylinositol (GPI)-anchor cleavage site. UMOD is a transmembrane-bound protein, which can be secreted into the urine by cleavage of the GPI-anchor [16] .
We here report three novel mutations in UMOD and confirm UMOD as the disease-causing gene. So far, eight mutations published are located in exon 4 and one mutation was found at the beginning of the neighboring exon 5 of the UMOD gene that encodes three EGF-like domains [10, 17] .
METHODS

Patients
We ascertained 25 MCKD families (224 individuals, of which 84 were affected). Fourteen families were from Germany, three from the United States, two each from the United Kingdom, Hungary, and Turkey, respectively, one each from Belgium and China, respectively. The age at diagnosis, the age at onset of end-stage renal disease (ESRD), hyperuricemia, imaging data, and biopsy results were reviewed if available. Clinical criteria necessary for inclusion were (1) compatibility of pedigree with autosomal-dominant inheritance, (2) chronic renal failure, (3) defective urine concentration (Ͻ800 mOsm/L after overnight dehydration) with polyuria (Ͼ3 L/day), and (4) at least one pedigree member with chronic renal failure in whom renal biopsy showed tubulointerstitial fibrosis with infiltrates, tubular atrophy, and thickening of the tubular basement membrane. Optional clinical criteria were normal or small-sized kidneys with occasional small corticomedullary cysts. Hyperuricemia was defined as serum uric acid concentration Ͼ1 SD greater than the normal values for age and gender (both genders 5 to 10 years, 4.1 Ϯ 1 mg/dL; female, 12 years, 4.5 Ϯ 0.9 mg/dL; 15 years, 4.5 Ϯ 0.9 mg/dL; Ն18 years, 4.0 Ϯ 0.7 mg/dL; male, 12 years, 4.4 Ϯ 1.1 mg/dL; 15 years, 5.5 Ϯ 1.1 mg/dL; Ն18 years, 6.2 Ϯ 0.8) [18] .
The study was approved by the Ethics Committee of the Albert-Ludwigs-University Freiburg and all participating family members provided informed consent.
Haplotype analysis
Genomic DNA was isolated by standard methods directly from blood samples using the QIAamp blood kit (Qiagen, Valencia, CA, USA) or from blood lymphocytes after Epstein-Barr virus (EBV) transformation. Haplotype analysis was performed in 224 individuals (including 84 affected individuals) and inferred in 18 additional individuals (nine additional affected individuals), using 13 consecutive polymorphic microsatellite markers that span the critical MCKD2 region in the following order: cen-D16S3116-D16S401-D16S3113-D16S420-D16S417-D16S412-D16-S3036-D16S3041-D16S3056-D16S501-D16S499-D16S-3060-D16S764-tel. Fluorescently labeled polymerase chain reaction (PCR) products were detected by a Genetic Analyzer 3100 (Applied Biosystems, Foster City, CA, USA) and were analyzed by the GENOTYPER software.
Mutational analysis of the UMOD gene
Mutational analysis was performed by exon PCR of the Uromodulin gene. Primer sequences were determined using the UCSC sequence (November 2002 freeze) encompassing the coding sequence of UMOD [19] . The following primers and conditions were employed: exon 3, 5Ј-CAATCAAAGCACTCCTTCCAG-3Ј and 5Ј-GACAGGTGCTACATTGCTTCC-3Ј; exon 4 was divided into two different overlapping parts: exon 4a, 5Ј-CCTGGAGAATGAGGGAAGG-3Ј and 5Ј-CTG GACGAGTACTGGCGC-3Ј; exon 4b, 5Ј-GGCAGCT ACTTGTGCGTATG-3Ј and 5Ј-CTCTGCAGTGCCT TTCCAG-3Ј; exon 5, 5Ј-GTCTCCCCACAGTCCTC ATC-3Ј and 5Ј-GGCAGTGACAGGTTTCTCAAC-3Ј; exon 6, 5Ј-GGCCCCCAAGCTATAGACAC-3Ј and 5Ј-CCATGAATTGCTTTCTTTATTTG-3Ј; exon 7,5Ј-TCATGCCCCTTTCTCTCATC-3Ј and 5Ј-GCTCATG GTTAAGGGGTTTG-3Ј; exon 8, 5Ј-TGCCTAGGA ATGCAAATCAG-3Ј and 5Ј-CCTTACCTGTCCTGG ATGATG-3Ј; exon 9, 5Ј-TCAGCTCTGCACTGATGA CAG-3Ј and 5Ј-TGGCCAAATGTCTTTGGTTAC-3Ј; exon 10, 5Ј-AACCACATTCAGGCTCCTTC-3Ј and 5Ј-AGGTGCCAGGCTCTGTTATC-3Ј; exon 11, 5Ј-GTCAGGATGCTTGCCAAATC-3Ј and 5Ј-CACTG CAGAAAGGACCTGAAC-3Ј; and exon 12, 5Ј-GG GTGTCCTCTTCTGATTGG-3Ј and 5Ј-CAGGTA CACCGTCACAAGTCC-3Ј using a "touch down" program with a starting annealing temperature of 72ЊC (exons 4a, 5, and 10), decreasing every step by 0.7ЊC for 24 times and a next round of amplification with an annealing temperature of 55ЊC for 20 times. An annealing temperature of 60ЊC was used for the exons 3, 4b, 8, and 9, 59ЊC for exons 7, 11, and 12, and 57ЊC for exon 6. PCR products were purified using the Marligen Rapid PCR Purification System (Ijamsville, MD, USA). Purified PCR products were sequenced, using a Genetic Analyzer 3700 (Applied Biosystems) and resulting sequences were evaluated with the Sequencher Software (Gene Codes, Ann Arbor, MI, USA).
RESULTS
Clinical data
The three families presenting with UMOD mutations included 12 living individuals affected with MCKD (three in F524, three in F739 and six in F762) (Fig. 1) . Six of 12 also suffered from hyperuricemia ( Table 1) . The patients presented with hyperuricemia between 17 and 59 years of age (Table 1) . ESRD developed between 29 years and 60 years. Imaging by magnetic resonance imaging (MRI) or ultrasound revealed in all families suspicious results with small kidneys, decreased parenchyma, or cysts. Occasional small cysts were only visible in three individuals by ultrasound (Table 1) . Renal histology in all cases was compatible with MCKD showing microcysts in four out of 12 cases and in the others dilated or atrophied tubules, global sclerosis, extensive tubulointerstitial atrophy with fibrosis, and signs of chronic diffuse inflammation (Table 1) .
Linkage analysis
In 25 families with 224 individuals, haplotype analysis for linkage to MCKD1 and MCKD2 was performed. In one kindred (F762), we found significant linkage to MCKD2. In six kindreds, significant linkage to chromosome 1 [logarithm of odds (LOD) score Ͼ3.0] or exclusion of linkage to chromosme 16 was found. Linkage for family F762 was previously published with a maxiumum multipoint LOD score of 3.75 in the interval between D16S3017 and D16S417 [20] . In 19 families too small for significant linkage, haplotype analysis was compatible with linkage to MCKD2.
Mutation analysis
We performed mutational analysis in affected individuals from 19 families compatible with linkage to MCKD2 examining all 10 coding exons of the UMOD gene by exon PCR and direct sequencing of the forward strands of exon PCR products.
We used an "affecteds only" approach for definition of the affected status of MCKD. Specifically, if diagnostic data supported MCKD, the affected status was assumed. If there was no data demonstrating the presence of MCKD, the disease status was determined as unknown, since there is age-related penetrance in MCKD. On this basis, there was full-cosegregation of all found heterozygous UMOD mutations and the affected status for MCKD.
In three of these families, novel mutations were detected (Fig. 1) . All three mutations were located in exon 4. In family F524, a nucleotide exchange (C779A) was found, resulting in the amino acid exchange Thr225Lys. The mutation was identified in all three affected brothers. Because I-1 in F524 is deceased, we cannot prove that he had the same mutation. His treatment of 15 years of dialysis makes his affected status very likely.
In family F739, a C849G mutation was detected, causing the amino acid exchange Cys248Trp. The mutation in F762 is an inframe deletion/insertion at position 383 (383del12/ins9) that deletes five amino acids and inserts four new amino acids.
Moreover, none of the mutations were found in 100 healthy controls. Therefore, our detected mutations are unlikely to be common polymorphisms.
In exon 6, an additional substitution (G1477T, Val458Leu) was found in two families that were compatible with linkage to 16p12. Nevertheless, this substitution was realized to be a new single nucleotide polymorphism (SNP) because we detected it in four healthy controls out of 100.
DISCUSSION
We detected three novel heterozygous mutations in the UMOD gene, thereby confirming that UMOD is the responsible gene for MCKD2. All detected mutations are found in exon 4 of UMOD, thus underlining the specific role of exon 4-encoded sequence in the generation of the MCKD2 renal phenotype.
In previous studies, abnormal localization of UMOD protein in the interstitium in MCKD patients was shown, suggesting UMOD as a candidate gene for MCKD [21] . By identifying three novel mutations, we confirmed the UMOD gene as the responsible gene for MCKD2. All mutations described here affect amino acids conserved in the cow, mouse, and rat (Fig. 2) . The mutation of F762 (383del12/ins9) is positioned in a domain of known function, the second calcium binding (cb) EGF-like domain. In F762, the cbEGF-like domain encoded by UMOD exon 4 is affected by a loss of five amino acids and their replacement by four new amino acids. Two of the five amino acids involved by the mutation of F762 are highly conserved in evolution, including the lower vertebrate zebrafish and the nematode Caenorhabditis elegans, in genes encoding EGF binding domains (for example, fibulin 1, an EGF containing extracellular matrix protein). In a number of human diseases, including Marfan syndrome, cerebral autodomal-dominant arteriopathy with subcortical infarcts and leukencephalopathy (CADASIL), Alagille syndrome, protein S defi- [20] . Arrows denote individuals in whom DNA was available for haplotype analysis. ciency, hemophilia B, and familial hypercholesterolaemia missense mutations within cbEGF domains were found [22] . Mutations in the Fibrillin-1 (FBN1) cause the Marfan syndrome. FBN1 reveals an equivalent domain forming a part of a calcium coordinating segment that stabilizes the tertiary structure [23] . Tandem FBN1 cbEGF domain pairs, when saturated with calcium, exhibit a rodlike conformation [22] . In Marfan syndrome, missense mutations in FBN1 have been described affecting the same cbEGF domain as the mutation of F762 (383del12/ ins9) [24, 25] . Smallridge et al [22] distinguished mutations within cbEGF domains as (1) mutations affecting cysteine residues and thereby disrupting disulphide bonds and (2) mutations affecting residues in the calcium-binding consensus sequence, which are likely to reduce calcium-binding affinity. As a consequence of the 383del12/ins9 mutation a cysteine is also affected, but the reason for the resulting impaired function remains theoretical because the importance of the four other replaced amino acids (ValProGlyGlu) is unclear. The Thr225Lys mutation of F524 and the Cys248Trp mutation of F739 are located in a region of unknown function that is also encoded by exon 4. Hart et al [10] and Turner et al [17] , repectively, also found two mutations in this region of exon 4, outside the known cbEGF-like domain. Interestingly, this region shows an identity of 56% with GP2, another ZP domain-containing protein.
All three mutations found are not only conserved in the above-mentioned animals but also in this conserved part of GP2 of Canis familiaris. Two of these mutations (Cys248Trp in F739, 383del12/ins9 in F762) involve cysteine residues, which are highly conserved in the UMOD protein throughout evolution including C. elegans (Fig. 2) . UMOD contains 48 cysteine residues per monomer form-ing 24 intramolecular disulfide bonds. The amino acid changes in F739 and F762 are therefore expected to change the molecular conformation through impaired intra-or intermolecular disulphide bond formation. The high cysteine content of THP and correct formation of the disulphide bonds were suspected to be the rate limiting step for the export of the premature THP out the endoplasmatic reticulum and that this regulates the efficiency of THP maturation [11] . Impaired disulphide binding is well known as a reason for other disorders, for example, diabetes insipidus centralis with a less stable vasopressin precursor, which accumulates in the endoplasmic reticulum [26] . The mutations we found are very likely to cause MCKD2 in these patients, even if none of them is a frameshift or a nonsense mutation. Also Hart et al [10] and Turner et al [17] did not detect any frameshift or nonsense mutation, which would cause a truncated protein. In addition, and surprisingly, all up to now identified mutations with the exception of one mutation at the beginning of the neighboring exon 5 are located in exon 4. All mutations take place in front of the ZP domain. The N-terminal half of exon 4 encodes the three known calcium-binding EGFlike domains [16] . The C-terminal part of exon 4 includes a nine amino acid long immunoglobulin light chainbinding domain [14] , which has not been affected by any mutation up to now. However, it seems that exon 4 plays an important role in the function of UMOD and that heterozygous mutations in this exon lead to the specific phenotype of MCKD2.
The clinical presentation of the phenotype has to be evaluated very carefully since renal cysts in imaging (only three of 12 affected individuals) and hyperuricemia (six of 12 affected individuals) do not occur in all of the patients. In all affected individuals, renal insufficiency (creatinine clearance Ͻ60 mL/min/1.73 m 2 ) was diagnosed. The age of onset is varied between 17 and 59 years of age. Hart et al [10] also described a kindred, in which the vast majority but not all affected individuals have hyperuricemia. This underlines the heterogeneity of the phenotype and might show that neither hyperuricemia nor cysts are an obligatory feature of the clinical presentation. At the moment, a significant genotype/phenotype correlation is not possible due to the limited number of different mutations detected so far.
Finally, it was surprising to us to find only three mutations in 19 families, which were compatible with linkage to 16p12. This may be explained by the small number of affected persons in most families, possibly resulting in false positive linkage result in an autosomal-dominant disease. Alternatively, a second gene for FJHN and MCKD2 might exist in the more centromeric region of UMOD in the region described by Kamatani et al [7] and which excludes the UMOD gene. Reports about additional mutations in MCKD2 and studies concerning the function of the UMOD protein will help to clarify the role of exon 4 for the pathogenesis of MCKD.
